Journal of AIDS & Clinical Research

Osmond D'Cruz

Publications

• Research Article
  Preclinical and First-In-Human Phase I Clinical Evaluation of Stampidine, a Potent Anti-HIV Pharmaceutical Drug Candidate
  Author(s): Pedro Cahn, Maria Jose Rolon, Ana Mirta Gun, Ines Ferrari, Ilker Dibirdik, Sanjive Qazi, Osmond D'Cruz, Kazim Sahin and Fatih UckunPedro Cahn, Maria Jose Rolon, Ana Mirta Gun, Ines Ferrari, Ilker Dibirdik, Sanjive Qazi, Osmond D'Cruz, Kazim Sahin and Fatih Uckun
  
  The rationally designed novel anti-HIV drug candidate Stampidine exhibited (a) remarkable subnanomolar to low nanomolar in vitro ARV potency against genotypically and phenotypically NRTI-resistant primary clinical HIV isolates, non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 isolates, clinical non-B subtype HIV- 1 isolates (subtypes A, C, F, and G) originating from South America, Asia, and sub-Saharan Africa with resistance to stavudine, adefovir and tenofovir, as well as recombinant HIV clones containing common patterns of RT mutations responsible for NRTI resistance such as multiple TAMs plus M184V, multiple TAMs plus T69 insertion, and Q151 complex (b) favorable, safety profile in mice, rats, dogs, and cats, and (c) promising prophylactic in vivo anti-retroviral activity in Hu-PBL-SCID mice as well as therapeutic anti-retrovir.. Read More»
  DOI: 10.4172/2155-6113.1000138

  Abstract PDF